Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2897-2908

  Bhosle, Jaishree ^a   Kiakos, Konstantinos ^a   Porter, Andrew C G ^b   Wu, Jenny ^a   Makris, Andreas ^c   Hartley, John A ^a   Hochhauser, Daniel ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE ALPHA (ATP HYDROLYSING); DOUBLE STRANDED DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GEFITINIB; HISTONE GAMMA H2AX; HISTONE H2AX; LAPATINIB; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK;

AMSACRINE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84890511103     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1049     Document Type: Article

References (50)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005;280:31182-9.
3. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 2008;7:69-77.
4. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011;71:1103-14.
5. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, et al. Interaction of the epidermal growth factor receptor and the DNAdependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006;5:209-18.
6. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006;5:1154-65.
7. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-7.
8. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008;68:9141-6.
9. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs M, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008;14:1266-73.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
11. Bernsdorf M, Ingvar C, Jorgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011;126:463-70.
12. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012;13:135-44.
13. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41.
14. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PloS One 2008;3:e2881.
15. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic- Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
16. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Trans Med 2010;2:16-17.
17. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13:3413-22.
18. Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11:1983-9.
19. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011; 13:1364-9.
20. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-smallcell lung cancer. J Clin Oncol 2009;27:264-70.
21. Carpenter AJ, Porter AC. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell 2004;15:5700-11.
22. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004;10:6476-86.
23. Wojewodzka M, Buraczewska I, Kruszewski M. A modified neutral comet assay: elimination of lysis at high temperature and validation of the assay with anti-single-stranded DNA antibody. Mutat Res 2002; 518:9-20.
24. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008;76:19-27.
25. Durand RE, Olive PL. Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 1981;41:3489-94.
26. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-50.
27. Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biol Ther 2003;2:233-5.
28. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17:421-33.
29. Perrin D, van Hille B, Hill BT. Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 1998;56: 503-7.
30. de Campos-Nebel M, Larripa I, Gonzalez-Cid M. Topoisomerase IImediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. PloS One 2010;5:e12541.
31. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, et al. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem 2008;283:23711-20.
32. Willmore E, Errington F, Tilby MJ, Austin CA. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem Pharmacol 2002; 63:1807-15.
33. Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009;15:6702-8.
34. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-37.
35. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin- based neoadjuvant chemotherapy. Cancer 2005;104:676-81.
36. Dickstein BM, Wosikowski K, Bates SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 1995; 110:205-11.
37. Kishida O, Miyazaki Y, Murayama Y, Ogasa M, Miyazaki T, Yamamoto T, et al. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 2005;55:584-94.
38. Krol J, Francis RE, Albergaria A, Sunters A, Polychronis A, Coombes RC, et al. The transcription factor FOXO3a is a crucial cellular targetof gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 2007; 6:3169-79.
39. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, et al. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Inter J Oncol 2009;35:57-68.
40. Wang IC, Meliton L, Ren X, Zhang Y, Balli D, Snyder J, et al. Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis. PloS One 2009;4:e6609.
41. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. Journal Biol Chem 2003;278:12696-702.
42. Grozav AG, Chikamori K, Kozuki T, Grabowski DR, Bukowski RM, Willard B, et al. Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity. Nucleic Acids Res 2009;37:382-92.
43. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
44. Vilain N, Tsai-Pflugfelder M, Benoit A, GasserSM, Leroy D.Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase II alpha. Nucleic Acids Res 2003;31:5714-22.
45. Bromberg KD, Burgin AB, Osheroff N. A two-drug model for etoposide action against human topoisomerase II alpha. J Biol Chem 2003;278: 7406-12.
46. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treatedwith the deoxyribonucleic acid intercalating agents 40-(9-acridinylamino) methanesulfon-m-aniside and adriamycin. Biochemistry 1981;20:6553-63.
47. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 1985;45:3143-9.
48. Sorensen M, Sehested M, Jensen PB. Effect of cellular ATP depletion on topoisomerase II poisons abrogation of cleavable complexes formation by etoposide but not amsacrine. Mol Pharmacol 1999;55: 424-31.
49. Rogojina AT, Nitiss JL. Isolation and characterisation of mAMSAhypersensitive mutants. J Biol Chem 2008;283:29239-50.
50. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signalling networks. Cell 2012;149:780-94.